These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21256862)

  • 1. Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome.
    Guzmán-Fulgencio M; Micheloud D; Lorente R; Bellón JM; Gomez MI; Gurbindo MD; León JA; Muñoz-Fernández MÁ; Resino S
    J Infect; 2011 Mar; 62(3):240-3. PubMed ID: 21256862
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
    Resino S; Palladino C; Lorente R; Micheloud D; Bellón JM; Larru B; Gutiérrez MD; de José MI; Polo R; Muñoz-Fernández MA;
    Pediatr Infect Dis J; 2010 Aug; 29(8):774-7. PubMed ID: 20375850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 4. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease.
    Guaraldi G; Ventura P; Garlassi E; Orlando G; Squillace N; Nardini G; Stentarelli C; Zona S; Marchini S; Moriondo V; Tebas P
    HIV Med; 2009 Jan; 10(1):28-34. PubMed ID: 19125962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
    Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term complications of antiretroviral therapy: lipoatrophy.
    Waters L; Nelson M
    Int J Clin Pract; 2007 Jun; 61(6):999-1014. PubMed ID: 17504362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
    Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
    Hartman K; Verweel G; de Groot R; Hartwig NG
    Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
    Mauss S
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():49-53. PubMed ID: 16385875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipodystrophy syndrome. Therapeutic progress is still pending].
    Weber K; Heiken H; Stoll M; Schmidt RE; Behrens G
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():28-32. PubMed ID: 15011581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.